Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

India breaks its vaccination record in 'birthday gift' to Modi

Published 17/09/2021, 16:21
Updated 17/09/2021, 18:26
© Reuters. FILE PHOTO: People wait in queues to receive a dose of COVISHIELD, a vaccine against coronavirus disease (COVID-19) manufactured by Serum Institute of India, outside a community centre in Kochi, India, September 7, 2021. REUTERS/Sivaram V

© Reuters. FILE PHOTO: People wait in queues to receive a dose of COVISHIELD, a vaccine against coronavirus disease (COVID-19) manufactured by Serum Institute of India, outside a community centre in Kochi, India, September 7, 2021. REUTERS/Sivaram V

(Corrects day in the first paragraph)

By Krishna N. Das

NEW DELHI (Reuters) -India gave a record 22.6 million vaccinations on Friday, three times the average daily total during the past month, as some states organised special inoculation drives on Prime Minister Narendra Modi's birthday.

The health minister called the vaccine milestone a birthday gift for Modi, who turned 71 and was criticised heavily for India's dramatic rise in infections and deaths in April and May.

"Every Indian would be proud of today’s record vaccination numbers," Modi said on Twitter (NYSE:TWTR). "Let us keep boosting vaccination to defeat COVID-19."

India's previous vaccination peak of 14.1 million was reached on Aug. 31, with a daily average of 7 million doses in the last 30 days.

Immunisations have surged in the past few weeks, thanks to a rapid rise in the production of the AstraZeneca (NASDAQ:AZN) shot by the Serum Institute of India (SII), the world's biggest vaccine maker.

SII would supply 200 million doses to India's immunisation programme this month, compared with around 150 million in the previous month, a government source who declined to be named said.

In addition, Bharat Biotech will supply 35 million doses of Covaxin this month, while Cadila Healthcare will join the inoculation drive next month by selling 10 million doses of its COVID-19 DNA vaccine.

The source said vaccinating Indians remained the priority for now though the country would eventually become a major supplier of affordable shots to the world. India, which stopped COVID-19 vaccine exports in April, now has the capacity to produce more than 2 billion doses a year.

The country of 1.35 billon people has administered more than 792 million doses, the most after China.

© Reuters. FILE PHOTO: People wait in queues to receive a dose of COVISHIELD, a vaccine against coronavirus disease (COVID-19) manufactured by Serum Institute of India, outside a community centre in Kochi, India, September 7, 2021. REUTERS/Sivaram V

India has given at least one dose to more than 62% of its 944 million adults and two doses to about 21%, with the aim of administering at least one dose to nearly all adults by the first half of next month.

The country has reported more than 33.38 million coronavirus cases and 444,248 deaths.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.